Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and pathological brain structure and function, and in building in vivo markers of disease and its progression. Commonly used methods can identify and precisely quantify subtle and spatially complex imaging patterns of brain change associated with brain diseases. However, the overarching premise of these methods is that the disease group is a homogeneous entity resulting from a single, unifying pathophysiological process that has a single imaging signature. This assumption ignores ample evidence for the heterogeneous nature of neurodegenerative diseases and neuropsychiatric disorders, resulting in incomplete or misleading descriptions. Accurate chara...
Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinic...
The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treat...
IntroductionModels characterizing intermediate disease stages of Alzheimer’s disease (AD) are needed...
Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and pat...
Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and pat...
Brain aging is a complex process that includes atrophy, vascular injury, and a variety of age-associ...
Brain aging is a complex process that includes atrophy, vascular injury, and a variety of age-associ...
Modern neuroimaging techniques allow us to investigate the brain in vivo and in high resolution, pro...
Disease heterogeneity is a significant obstacle to understanding pathological processes and deliveri...
Understanding Alzheimer’s disease (AD) heterogeneity is important for understanding the underlying p...
This thesis sets out to investigate the Alzheimer's disease (AD) heterogeneity in an unsupervised fr...
Dementia is a highly heterogeneous condition, with pronounced individual differences in age of onset...
Alzheimer’s disease (AD) affects millions of people and is a major rising problem in health care wor...
Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by loss of memor...
Most neuro-related diseases and disabling diseases display significant heterogeneity at the imaging ...
Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinic...
The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treat...
IntroductionModels characterizing intermediate disease stages of Alzheimer’s disease (AD) are needed...
Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and pat...
Automated quantitative neuroimaging analysis methods have been crucial in elucidating normal and pat...
Brain aging is a complex process that includes atrophy, vascular injury, and a variety of age-associ...
Brain aging is a complex process that includes atrophy, vascular injury, and a variety of age-associ...
Modern neuroimaging techniques allow us to investigate the brain in vivo and in high resolution, pro...
Disease heterogeneity is a significant obstacle to understanding pathological processes and deliveri...
Understanding Alzheimer’s disease (AD) heterogeneity is important for understanding the underlying p...
This thesis sets out to investigate the Alzheimer's disease (AD) heterogeneity in an unsupervised fr...
Dementia is a highly heterogeneous condition, with pronounced individual differences in age of onset...
Alzheimer’s disease (AD) affects millions of people and is a major rising problem in health care wor...
Alzheimer’s disease (AD) is the most common cause of dementia. It is characterized by loss of memor...
Most neuro-related diseases and disabling diseases display significant heterogeneity at the imaging ...
Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinic...
The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treat...
IntroductionModels characterizing intermediate disease stages of Alzheimer’s disease (AD) are needed...